274 related articles for article (PubMed ID: 28521284)
21. Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vγ9Vδ2 T Lymphocytes In Vitro.
Liu X; Feng T; Gong T; Shen C; Zhu T; Wu Q; Li Q; Li H
Biomed Res Int; 2015; 2015():317801. PubMed ID: 25984529
[TBL] [Abstract][Full Text] [Related]
22. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
[TBL] [Abstract][Full Text] [Related]
23. The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.
Gertner-Dardenne J; Fauriat C; Orlanducci F; Thibult ML; Pastor S; Fitzgibbon J; Bouabdallah R; Xerri L; Olive D
Blood; 2013 Aug; 122(6):922-31. PubMed ID: 23692853
[TBL] [Abstract][Full Text] [Related]
24. Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.
Dunne MR; Mangan BA; Madrigal-Estebas L; Doherty DG
Mediators Inflamm; 2010; 2010():704941. PubMed ID: 21403900
[TBL] [Abstract][Full Text] [Related]
25. The multifunctionality of human Vγ9Vδ2 γδ T cells: clonal plasticity or distinct subsets?
Kabelitz D; He W
Scand J Immunol; 2012 Sep; 76(3):213-22. PubMed ID: 22670577
[TBL] [Abstract][Full Text] [Related]
26. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome Signature of Vγ9Vδ2 T Cells Treated With Phosphoantigens and Notch Inhibitor Reveals Interplay Between TCR and Notch Signaling Pathways.
Madhok A; Bhat SA; Philip CS; Sureshbabu SK; Chiplunkar S; Galande S
Front Immunol; 2021; 12():660361. PubMed ID: 34526984
[TBL] [Abstract][Full Text] [Related]
28. Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells.
Caccamo N; La Mendola C; Orlando V; Meraviglia S; Todaro M; Stassi G; Sireci G; Fournié JJ; Dieli F
Blood; 2011 Jul; 118(1):129-38. PubMed ID: 21505189
[TBL] [Abstract][Full Text] [Related]
29. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
30. TCR repertoire analysis reveals phosphoantigen-induced polyclonal proliferation of Vγ9Vδ2 T cells in neonates and adults.
Fichtner AS; Bubke A; Rampoldi F; Wilharm A; Tan L; Steinbrück L; Schultze-Florey C; von Kaisenberg C; Prinz I; Herrmann T; Ravens S
J Leukoc Biol; 2020 Jun; 107(6):1023-1032. PubMed ID: 32064671
[TBL] [Abstract][Full Text] [Related]
31. Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells.
Devilder MC; Allain S; Dousset C; Bonneville M; Scotet E
J Immunol; 2009 Sep; 183(6):3625-33. PubMed ID: 19710464
[TBL] [Abstract][Full Text] [Related]
32. Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.
Sawaisorn P; Gaballa A; Saimuang K; Leepiyasakulchai C; Lertjuthaporn S; Hongeng S; Uhlin M; Jangpatarapongsa K
Sci Rep; 2024 Jan; 14(1):1291. PubMed ID: 38221530
[TBL] [Abstract][Full Text] [Related]
33. Alpaca (
Fichtner AS; Karunakaran MM; Gu S; Boughter CT; Borowska MT; Starick L; Nöhren A; Göbel TW; Adams EJ; Herrmann T
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6697-6707. PubMed ID: 32139608
[TBL] [Abstract][Full Text] [Related]
34. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
35. Skewed representation of functionally distinct populations of Vgamma9Vdelta2 T lymphocytes in aging.
Re F; Poccia F; Donnini A; Bartozzi B; Bernardini G; Provinciali M
Exp Gerontol; 2005; 40(1-2):59-66. PubMed ID: 15664733
[TBL] [Abstract][Full Text] [Related]
36. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
37. Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vγ9Vδ2 T cells in low levels of IL-2.
Cho HW; Kim SY; Sohn DH; Lee MJ; Park MY; Sohn HJ; Cho HI; Kim TG
J Leukoc Biol; 2016 Apr; 99(4):521-9. PubMed ID: 26561569
[TBL] [Abstract][Full Text] [Related]
38. Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists.
Wiemer DF; Wiemer AJ
Biochem Pharmacol; 2014 Jun; 89(3):301-12. PubMed ID: 24680696
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.
Lesport E; Baudhuin J; Sousa S; LeMaoult J; Zamborlini A; Rouas-Freiss N; Carosella ED; Favier B
Cell Mol Life Sci; 2011 Oct; 68(20):3385-99. PubMed ID: 21337044
[TBL] [Abstract][Full Text] [Related]
40. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.
Sicard H; Ingoure S; Luciani B; Serraz C; Fournié JJ; Bonneville M; Tiollier J; Romagné F
J Immunol; 2005 Oct; 175(8):5471-80. PubMed ID: 16210655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
